{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:11:14Z","timestamp":1774293074634,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["454382"],"award-info":[{"award-number":["454382"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:28:26Z","timestamp":1622849306000},"page":"129-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02\/ALLG NHL15"],"prefix":"10.1016","volume":"152","author":[{"given":"Michael P.","family":"MacManus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Capp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.05.004_bib1","first-page":"153","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"66","author":"Raderer","year":"2016","journal-title":"CA \u2013 Cancer J Clin"},{"key":"10.1016\/j.ejca.2021.05.004_bib2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","author":"Ferreri","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3324\/haematol.2011.040402","article-title":"Genomic profiles of MALT lymphomas: variability across anatomical sites","volume":"96","author":"Kwee","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2021.05.004_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.05.004_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0266-4356(94)90055-8","article-title":"Bilateral parotid MALT lymphoma and Sjogren's syndrome","volume":"32","author":"Stewart","year":"1994","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ejca.2021.05.004_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.01.009","article-title":"Review article: mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. Biology and treatment","volume":"100","author":"Annibali","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2021.05.004_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/tbj.12773","article-title":"Bilateral MALT lymphoma of the breast","volume":"23","author":"Gonzalez Lopez","year":"2017","journal-title":"Breast J"},{"key":"10.1016\/j.ejca.2021.05.004_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1440-1673.2006.01642.x","article-title":"Positron emission tomography of stage IV mucosa-associated lymphoid tissue lymphoma confined to the four major salivary glands","volume":"51","author":"Mac Manus","year":"2007","journal-title":"Australas Radiol"},{"key":"10.1016\/j.ejca.2021.05.004_bib9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3324\/haematol.2012.083386","article-title":"Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review","volume":"98","author":"van den Brand","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2021.05.004_bib10","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2021.05.004_bib11","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(95)90113-2","article-title":"Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group","volume":"345","author":"Bayerdorffer","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.05.004_bib12","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00280-011-1631-y","article-title":"t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement","volume":"68","author":"Kuo","year":"2011","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2021.05.004_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jjco\/hyt097","article-title":"A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy","volume":"43","author":"Abe","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2015.08.029","article-title":"Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: results of a prospective study with a long term follow-up","volume":"117","author":"Ruskone-Fourmestraux","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1023\/A:1008278725106","article-title":"Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: clinical and therapeutic features of 24 localized patients","volume":"8","author":"Zinzani","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib16","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1056\/NEJMicm1011193","article-title":"Images in clinical medicine. Sjogren's syndrome and MALT lymphoma","volume":"364","author":"Ornetti","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.004_bib17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdn049","article-title":"Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma","volume":"19","author":"Troch","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(05)65578-X","article-title":"Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori","volume":"348","author":"Alkan","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.05.004_bib19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.1984","article-title":"Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions","volume":"209","author":"Chanudet","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2021.05.004_bib20","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.2005.02.9025","article-title":"Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma","volume":"24","author":"Grunberger","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib21","first-page":"211","article-title":"Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma","volume":"7","author":"McLaughlin","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0360-3016(01)01549-8","article-title":"Stage I and II MALT lymphoma: results of treatment with radiotherapy","volume":"50","author":"Tsang","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.004_bib23","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib24","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib25","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.clml.2020.08.014","article-title":"Effectiveness and safety of subcutaneous rituximab for patients with gastric MALT lymphoma: a case-control comparison with intravenous rituximab","volume":"21","author":"Rotkopf","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2021.05.004_bib26","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/annonc\/mdx025","article-title":"Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma","volume":"28","author":"Teckie","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib27","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.004_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.05.004_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428194.2019.1644333","article-title":"Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function","volume":"61","author":"Gunther","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2021.05.004_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2010.09.056","article-title":"Ocular risks from orbital and periorbital radiation therapy: a critical review","volume":"79","author":"Jeganathan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.004_bib32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00535-018-1517-4","article-title":"Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trial","volume":"54","author":"Schmelz","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ejca.2021.05.004_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijrobp.2019.02.002","article-title":"Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"104","author":"Pinnix","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.004_bib34","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1182\/blood-2007-08-109611","article-title":"Borrelia infection and risk of non-Hodgkin lymphoma","volume":"111","author":"Schollkopf","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.05.004_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1309\/AJCPXMDRT1SY6KIV","article-title":"Chlamydia psittaci infection in nongastrointestinal extranodal MALT lymphomas and their precursor lesions","volume":"135","author":"Aigelsreiter","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2021.05.004_bib36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ijid.2008.01.011","article-title":"The seroepidemiology of Helicobacter pylori infection in Australia","volume":"12","author":"Moujaber","year":"2008","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ejca.2021.05.004_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5694\/j.1326-5377.1997.tb125076.x","article-title":"Helicobacter pylori infection in an Australian regional city: prevalence and risk factors","volume":"167","author":"Peach","year":"1997","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejca.2021.05.004_bib38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pathol.2016.03.014","article-title":"Low level autoantibodies can be frequently detected in the general Australian population","volume":"48","author":"Deshpande","year":"2016","journal-title":"Pathology"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:03Z","timestamp":1760733123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":38,"alternative-id":["S0959804921002938"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02\/ALLG NHL15","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}